Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

Durvalumab + Olaparib

Trade Name:
Imfinzi + Lynparza
Company:
Status:
Currently Enrolling
Agent Chaperone(s):
Treatment Protocol:
Durvalumab is administered intravenously at 1500 mg once every 4 weeks (q4w) with Olaparib twice a day at 100 mg BID and Paclitaxel weekly at 80 mg/m2 for 12 total weeks. This regimen is followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
May 3, 2018
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
Agent Description:

Durvalumab is a checkpoint inhibitor immunotherapy agent -- a human immunoglobulin monoclonal antibody (mAb). It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for treating patients with locally advanced or metastatic urothelial carcinoma under certain conditions. Olaparib is a Poly(ADP-ribose) polymerase (PARP) Inhibitor.

Olaparib is a PARP inhibitor, inhibiting poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. It is approved for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. Olaparib is the first PARP inhibitor to be approved by the FDA for gBRCAm metastatic breast cancer.

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link